Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
study to assess maximum tolerated dose (MTD), safety, tolerability and activity of IGEV
(Ifosfamide, Gemcitabine,Vinorelbine, Prednisolone) + Panobinostat new combination in order
to determine the recommended phase II dose